INDBInternet News Database 2.5 Updated 1 min ago · 288 sources Show or hide images Light or dark

Results for “Ema Ushioda”

1 source

Who is covering this

DW NewsCenter
Truth score 451
Centre 100%100%
DW NewsCenter

Does it still make sense to learn a new language in the age of AI?

With the rapid advancement in AI translation technology, some linguists predict that human interpreters may soon be obsolete. Does that mean learning a foreign language now is a waste of time? DW's Amien Essif spoke to polyglot...

Lean: Center VideoFactuality: Very highCountry: GermanyFunding: Public broadcasterOwner: German Government
Full coverage
Coverage breakdown
Funding
Public broadcaster100%
Countries
Germany100%
Media ownership
German Government100%
Avg reliability85
Low-credibility share0%
Fact / opinion1/0
State media0%
More analysis
Truth score: 45 (Limited corroboration) Propaganda risk: 0 Trending: Low Sources: 1 Reliability: 85 Bias severity: 0 Risk: 0Sentiment: 0Sensationalism: 0 Amplification: 0

How we score

Analyze: Misinfo Radar
Like
Health
1 source

Who is covering this

MedscapeCenter
Truth score 38
Centre 100%100%
MedscapeCenter

EMA Reviews Allergic Reactions With Immunoglobulin Batches

EMA’s safety committee is reviewing increased reporting of hypersensitivity reactions, including anaphylaxis, linked to specific batches of human normal immunoglobulin medicines. Medscape News Europe

Lean: Center Fact-focusedFactuality: Mostly factualCountry: United StatesFunding: CorporateOwner: Independent
Full coverage
Coverage breakdown
Funding
Corporate100%
Countries
United States100%
Media ownership
Independent100%
Avg reliability65
Low-credibility share0%
Fact / opinion1/0
State media0%
More analysis
Truth score: 38 (Weakly supported) Propaganda risk: 0 Trending: Low Sources: 1 Reliability: 65 Bias severity: 0 Risk: 0Sentiment: 0Sensationalism: 0 Amplification: 0

How we score

Analyze: Story Timeline
Like
Health
1 source

Who is covering this

MedscapeCenter
Truth score 38
Centre 100%100%
MedscapeCenter

EMA Reviews Depression, Anxiety Drug Over Adverse Effects

Deanxit (flupentixol-melitracen) is under review after reports of movement disorders and memory and thinking problems, with some symptoms persisting after treatment was stopped. Medscape News Europe

Lean: Center Fact-focusedFactuality: Mostly factualCountry: United StatesFunding: CorporateOwner: Independent
Full coverage
Coverage breakdown
Funding
Corporate100%
Countries
United States100%
Media ownership
Independent100%
Avg reliability65
Low-credibility share0%
Fact / opinion1/0
State media0%
More analysis
Truth score: 38 (Weakly supported) Propaganda risk: 0 Trending: Low Sources: 1 Reliability: 65 Bias severity: 0 Risk: 0Sentiment: 0Sensationalism: 0 Amplification: 0

How we score

Analyze: Compare coverage
Like